These findings suggested that elevation of SSP by up-regulation of PHGDH, PSAT1, and PSPH is a common mechanism underlying TKI resistance in HCC and thus targeting PHGDH may be a promising combinational therapy strategy to improve the efficacy of TKI treatment in HCC patient. The gene discussed is PSPH; the disease is hepatocellular carcinoma.